News
Genetic Analysis strengthens and future-proofs the organization
OSLO, NORWAY, January 31, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA is…
Genetic Analysis’ CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
OSLO, NORWAY, January 27, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA’s Chief…
Genetic Analysis AS achieves Thai FDA License for GA-map® Dysbiosis Test in Thailand
OSLO, NORWAY – 19 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) are happy to announce that Thailand Food…
Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map® technology in India
OSLO, NORWAY – 16 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a Tech Transfer Agreement with…
Genetic Analysis AS enters an agreement with Hausen Bernstein Co. Ltd. to launch GA-map® technology in Thailand
OSLO, NORWAY – November 30, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a tech transfer and distribution…
Genetic Analysis AS announces the outcome of the warrant exercise
Oslo, Norway, November 21, 2022 – On November 16, 2022, the exercise period for Genetic Analysis AS’s (“GA” or the…
Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map® in Europe
OSLO, NORWAY – 7 November 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) today announces that GA has entered into…
Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis
Oslo, Norway, November 2, 2022 – On November 2, 2022, the exercise period for the warrants of series TO 1…
Interim report January – September 2022
Oslo, Norway, November 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the…
Genetic Analysis appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
Oslo, Norway, September 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) has appointed Sedermera Corporate Finance as the…
Interim report January – June 2022
Oslo, Norway, August 18, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the…
Genetic Analysis and Servatus enter Strategic Collaboration Agreement to develop new microbiome diagnostic and therapeutic solutions
The Strategic Collaboration Agreement will enable both parties to utilise extensive knowledge sharing for microbiome diagnostics and biotherapeutics development Genetic…
Genetic Analysis AS: Mandatory notification of trade – Primary Insider
OSLO, NORWAY – 20 May 2022: Genetic Analysis AS (“GA” or “the Company”) announce that a member of the management…
Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arabic Emirates (UAE) market
OSLO, NORWAY – May 19, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) hereby announces that GA has entered a…
Interim report January – March 2022
Oslo, Norway, May 13, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the…